Application Nr Approved Date Route Status External Links
ANDA201581 None Oral None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Montelukast Sodium Tablets Are A Leukotriene Receptor Antagonist Indicated For: • Prophylaxis And Chronic Treatment Of Asthma In Patients 12 Months Of Age And Older ( 1.1 ). • Acute Prevention Of Exercise-Induced Bronchoconstriction (Eib) In Patients 6 Years Of Age And Older (1.2 ). • Relief Of Symptoms Of Allergic Rhinitis (Ar): Seasonal Allergic Rhinitis (Sar) In Patients 2 Years Of Age And Older,and Perennial Allergic Rhinitis (Par) In Patients 6 Months Of Age And Older. Reserve Use For Patients Who Have An Inadequate Response Or Intolerance To Alternative Therapies (1.3 ). 1.1 Asthma Montelukast Sodium Is Indicated For The Prophylaxis And Chronic Treatment Of Asthma In Adults And Pediatric Patients 12 Months Of Age And Older. 1.2 Exercise-Induced Bronchoconstriction (Eib) Montelukast Sodium Is Indicated For Prevention Of Exercise-Induced Bronchoconstriction (Eib) In Patients 6 Years Of Age And Older. 1.3 Allergic Rhinitis Montelukast Sodium Is Indicated For The Relief Of Symptoms Of Seasonal Allergic Rhinitis In Patients 2 Years Of Age And Older And Perennial Allergic Rhinitis In Patients 6 Monthsof Age And Older. Because The Benefits Of Montelukast Sodium May Not Outweigh The Risk Of Neuropsychiatric Symptoms In Patients With Allergic Rhinitis [See Warnings And Precautions ( 5.1 )], Reserve Use For Patients Who Have An Inadequate Response Or Intolerance To Alternative Therapies.

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Montelukast Sodium MONTELUKAST SODIUM ZINC3831151

Comments